ocu410
·Code: RORA
ocu410: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Ocugen, Inc. (OCGN) | Phase 2/Phase 3 |
Clinical Trials (1)
A Phase 1/2 Study to Assess the Safety And Efficacy Of OCU410 For Geographic Atrophy Secondary To Dry Age-Related Macular Degeneration
Frequently asked questions
Who is developing ocu410?
ocu410 is being developed by Ocugen, Inc..
How many clinical trials involve ocu410?
BioSniper tracks 1 clinical trial involving ocu410.
Get deeper analysis on ocu410
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis